Sanofi expects Q4 growth: CEO

Share this article:

Sanofi chief executive Chris Viehbacher tells Bloomberg the French drug maker is poised to put recent lackluster results behind. “Our view is that particularly in the 4Q, the company returns to growth for the next period,” he told the news service, which notes that the CEO did not specify if that meant growth in terms of sales or growth in terms of profit.

The company has muddled through a series of patent losses, which contributed to last quarter's sales which were 9.7% less than 2012's second quarter results. Viehbacher characterized results at the time as frustrating. Since then the company's news has included rolling out the half-unit insulin pen for children called JuniorSTAR in the EU this September, offering it a foothold in Novo's pediatric territory.

This is in addition to EU-cleared offerings like MyStar Extra, a self-monitoring blood glucose meter, which “provides robust estimates” of a patient's A1C value and a lancing device for blood sugar tests called SylkFeel. Type-two diabetes GLP-1 medication Lyxumia (lixisenatide) remains off the list of near-term potential products. The company pulled the drug from the FDA's list of reviewable drugs, saying it wanted more data to come in before handing over to the regulator.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.